Differentiation of renal cell carcinoma subtypes with different iodine quantification methods using single-phase contrast-enhanced dual-energy CT: areal vs. volumetric analyses
- 18 July 2017
- journal article
- research article
- Published by Springer Nature in Abdominal Radiology
- Vol. 43 (3) , 672-678
Abstract
Purpose To investigate the possibility of iodine quantification during a single nephrographic phase in characterizing renal cell carcinoma (RCC) subtypes and if there is a difference between areal and volumetric iodine quantification methods. Materials and methods This retrospective study included 110 patients with 113 histopathologically confirmed RCCs scanned by dual-energy CT at the nephrographic phase before surgeries. For each lesion, an areal measurement of the iodine concentration with maximum enhancement (I max enhan) and the iodine concentration with maximum area among slices (I max area), as well as a volumetric iodine concentration of the whole-tumor (I volume), were evaluated by two independent radiologists. The diagnostic performances in a single nephrographic phase for characterizing RCC subtypes were evaluated, and three iodine quantification methods were compared with each other. Results There were significant differences (clear cell vs. papillary and clear cell vs. chromophobe RCC) and no significant differences (papillary vs. chromophobe RCC) at the nephrographic phase in all three methods. The area under the receiver operating characteristic (ROC) curve (AUC) derived from the I max enhan for discriminating clear cell from papillary RCC was significantly higher than that derived from the I max area (P = 0.0357) and the I volume (P = 0.0206), and no significant differences existed among the three methods in distinguishing clear cell RCC from chromophobe RCC. The reliability of all three parameters was very high with an interclass correlation coefficient (ICC) exceeding 0.8. Conclusions Iodine quantification in a single nephrographic phase can be used to differentiate RCC subtypes preoperatively, and the areal maximum enhancement iodine quantification would probably be the most appropriate approach.Keywords
Funding Information
- National Science Foundation of Shanghai (14ZR1438400)
This publication has 22 references indexed in Scilit:
- Update on Renal Mass BiopsyCurrent Urology Reports, 2017
- Renal Mass Biopsy: Always, Sometimes, or Never?European Urology, 2016
- EAU Guidelines on Renal Cell Carcinoma: 2014 UpdateEuropean Urology, 2015
- Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic ComplexityEuropean Urology, 2015
- A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinomaCancer Treatment Reviews, 2014
- The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal NeoplasiaAmerican Journal of Surgical Pathology, 2013
- Clear Cell Renal Cell Carcinoma: Discrimination from Other Renal Cell Carcinoma Subtypes and Oncocytoma at Multiphasic Multidetector CTRadiology, 2013
- Histological Subtype is an Independent Predictor of Outcome for Patients With Renal Cell CarcinomaJournal of Urology, 2010
- Papillary Renal Cell Carcinoma: Radiologic-Pathologic Correlation and Spectrum of DiseaseRadioGraphics, 2009
- Solid Renal Cortical Tumors: Differentiation with CTRadiology, 2007